Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$5.35
+3.5%
$6.40
$2.78
$8.85
$29.05M1.0329,320 shs9,079 shs
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
$28.04
$28.04
$5.62
$28.54
$807.55M2.74499,313 shs35,036 shs
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$17.61
-1.4%
$19.32
$10.65
$22.09
$1.26B0.27349,731 shs477,276 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$38.15
-3.9%
$42.07
$15.50
$52.57
$2.39B1.9496,438 shs424,399 shs
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+5.52%-8.39%-9.63%+2.88%+40.05%
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-1.40%+4.32%-11.82%-3.35%+57.94%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-3.93%+0.10%-3.49%-13.98%+81.24%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.8479 of 5 stars
3.55.00.00.00.03.30.6
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
2.2687 of 5 stars
3.51.00.00.02.43.30.6
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.4499 of 5 stars
2.50.00.04.31.90.80.6
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.00
Buy$15.50189.72% Upside
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
N/AN/AN/AN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
3.00
Buy$30.0070.36% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.00
Buy$47.2023.72% Upside
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A

Current Analyst Ratings

Latest ZIOP, APRE, DOVA, RYTM, and KNSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$25.00 ➝ $30.00
4/23/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
4/18/2024
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$53.00 ➝ $52.00
4/10/2024
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
4/2/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$28.00 ➝ $30.00
3/27/2024
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$9.00 ➝ $11.00
3/26/2024
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
2/28/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$28.00
2/22/2024
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
1/26/2024
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$580K50.09N/AN/A$4.54 per share1.18
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
$10.35M78.02N/AN/A$2.71 per share10.35
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$270.26M4.60N/AN/A$6.23 per share2.83
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$77.43M29.63N/AN/A$2.87 per share13.29
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$14.29M-$3.99N/AN/AN/AN/A-65.58%-52.37%5/20/2024 (Estimated)
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
-$72.28M-$2.60N/AN/AN/A-544.09%-101.60%-67.21%N/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$14.08M$0.11160.11N/A2.78%-7.32%-6.15%7/23/2024 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$184.68M-$3.20N/AN/AN/A-238.50%-96.02%-55.02%5/7/2024 (Confirmed)
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest ZIOP, APRE, DOVA, RYTM, and KNSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$2.12N/A+$2.12N/AN/AN/A  
4/23/2024Q1 2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-$0.14-$0.25-$0.11-$0.25$76.97 million$79.90 million    
3/26/2024Q4 2023
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.56-$0.92-$0.36-$0.92$0.33 million$0.01 million
2/28/2024Q4 2023
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-$0.11$0.04+$0.15-$0.27$72.31 million$83.40 million
2/22/2024Q4 2023
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.70-$0.70N/A-$0.70$25.38 million$24.23 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
5.13
5.13
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
0.41
5.64
5.37
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
N/A
4.34
3.85
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
5.58
5.43
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
75.43 million4.30 millionNo Data
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
11528.80 millionN/AOptionable
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
29770.61 million32.32 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
22660.14 million57.31 millionOptionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

ZIOP, APRE, DOVA, RYTM, and KNSA Headlines

SourceHeadline
Childhood CancersChildhood Cancers
curetoday.com - February 17 at 5:57 PM
Alx Oncology Holdings (ALXO)Alx Oncology Holdings (ALXO)
investing.com - February 10 at 8:15 PM
Pediatric Hematology-Oncology FellowshipPediatric Hematology-Oncology Fellowship
bcm.edu - February 5 at 8:39 AM
Alaunos Therapeutics: Other Events, Financial Statements And ExhibitsAlaunos Therapeutics: Other Events, Financial Statements And Exhibits
cbonds.com - January 31 at 9:44 AM
CG Oncology IncCG Oncology Inc
reuters.com - January 31 at 4:43 AM
Oncology Nurses Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer PatientsOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients
medscape.com - December 21 at 3:43 PM
Immuno-OncologyImmuno-Oncology
ajmc.com - December 19 at 3:21 PM
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
markets.businessinsider.com - December 18 at 8:18 AM
Exploring Patient-Centered Handoffs in Surgical OncologyExploring Patient-Centered Handoffs in Surgical Oncology
medscape.com - December 10 at 7:36 PM
Association of Community Cancer CentersAssociation of Community Cancer Centers
ajmc.com - October 14 at 2:50 PM
Oncology News and ResearchOncology News and Research
news-medical.net - September 19 at 5:53 PM
WBSPH 2024 - OncologyWBSPH 2024 - Oncology
newsweek.com - September 15 at 8:49 PM
Kris on OncologyKris on Oncology
medscape.com - September 6 at 11:16 PM
Gauging Ziopharms Chances for Positive Sarcoma Drug Trial ResultsGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results
thestreet.com - August 29 at 6:23 AM
Oncology Cases & QuizzesOncology Cases & Quizzes
medscape.com - August 14 at 6:15 PM
Ziopharm’s palifosfamide fails in first-line STS…Ziopharm’s palifosfamide fails in first-line STS…
investing.com - June 21 at 12:05 AM
Weber on OncologyWeber on Oncology
medscape.com - June 19 at 2:11 PM
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in MelanomaA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
ascopubs.org - June 17 at 8:43 AM
ALX Oncology Holdings Inc Ordinary SharesALX Oncology Holdings Inc Ordinary Shares
morningstar.com - June 15 at 6:54 PM
Division of Pediatric Hematology and OncologyDivision of Pediatric Hematology and Oncology
slu.edu - June 13 at 3:50 PM
Division of Hematology and Medical OncologyDivision of Hematology and Medical Oncology
slu.edu - June 13 at 3:50 PM
Intratumoral Cancer Therapies Global Market Report 2023Intratumoral Cancer Therapies Global Market Report 2023
finance.yahoo.com - June 9 at 1:32 PM
Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.coNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co
marketwatch.com - May 11 at 9:52 PM
VC Identifies 3 Startups That Will Shake Up the Future of Cancer CareVC Identifies 3 Startups That Will Shake Up the Future of Cancer Care
medcitynews.com - May 10 at 1:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aprea Therapeutics logo

Aprea Therapeutics

NASDAQ:APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Dova Pharmaceuticals logo

Dova Pharmaceuticals

NASDAQ:DOVA
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.
Kiniksa Pharmaceuticals logo

Kiniksa Pharmaceuticals

NASDAQ:KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Rhythm Pharmaceuticals logo

Rhythm Pharmaceuticals

NASDAQ:RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
ZIOPHARM Oncology logo

ZIOPHARM Oncology

NASDAQ:ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.